We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
-9.55%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$541M
AUM Growth
+$81.3M
Cap. Flow
+$124M
Cap. Flow %
23%
Top 10 Hldgs %
62%
Holding
53
New
14
Increased
8
Reduced
19
Closed
9

Top Buys

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$22.3M
2
XENT
Intersect ENT, Inc
XENT
+$14.2M
3
VRAY
ViewRay, Inc.
VRAY
+$12.6M
4
WMGI
Wright Medical Group Inc
WMGI
+$11.7M
5
ABBV icon
AbbVie
ABBV
+$10.6M

Top Sells

Rank Stock Value
1
PETX
Aratana Therapeutics, Inc.
PETX
+$37.5M
2
NVRO
NEVRO CORP.
NVRO
+$25.6M
3
HRTX icon
Heron Therapeutics
HRTX
+$10.3M
4
CPRX
Catalyst Pharmaceutical
CPRX
+$10M
5
ZGNX
Zogenix, Inc.
ZGNX
+$9.53M

Sector Composition

Rank Sector Weight
1 Healthcare 53.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVTX icon
51
PUT
Travere Therapeutics
TVTX
$5.27B
– –
-500,000
Closed -$10M
ADMS
52
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-441,088
Closed -$2.73M
PETX
53
DELISTED
Aratana Therapeutics, Inc.
PETX
– –
-7,258,135
Closed -$37.5M
1 2
3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q3 2019 Portfolio in Review

As of Q3 2019, Broadfin Capital held 53 positions worth $541M, up 18% from $460M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Broadfin Capital deployed $124M of net new capital in Q3 2019, opening 14 new positions and adding to 8 existing holdings. Its largest new stake was Intersect ENT, Inc: 779,134 shares worth $13.3M.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 78% a quarter earlier.

On the sell side, the largest reduction was NEVRO CORP., an estimated $25.6M trimmed.

  • Broadfin Capital's largest Q3 2019 buy was Intersect ENT, Inc: 779,134 shares worth $13.3M.
  • Broadfin Capital added most to Amarin Corp in Q3 2019, an estimated $22.3M increase.
  • Broadfin Capital's biggest Q3 2019 reduction was NEVRO CORP., cutting an estimated $25.6M.
  • Broadfin Capital fully exited Aratana Therapeutics, Inc. in Q3 2019, selling an estimated $37.5M.
  • Broadfin Capital's ten largest holdings make up 62% of its $541M portfolio in Q3 2019.
  • Broadfin Capital opened 14 new positions and closed 9 in Q3 2019.
  • Broadfin Capital's portfolio value rose 18% quarter-over-quarter to $541M.

Based on Broadfin Capital's 13F filing for Q3 2019, filed 14 Nov 2019.